Personalized Neoantigen-Based Cancer Treatment System

A novel, adaptive cancer treatment system utilizing tucaresol analogs, machine learning, and real-time genomic analysis to optimize treatment regimens and improve patient outcomes.

The original patent relates to compositions containing tucaresol or its analogs for cancer treatment. However, the patent's limitation lies in its focus on fixed compositions and lack of adaptability to individual patient needs. The present inventive concept addresses this limitation by introducing a personalized, adaptive approach to cancer treatment.

The inventive concept comprises a tucaresol analog library, a neoantigen prediction module, and a machine learning-based treatment optimization engine. The system administers a tucaresol-based composition, monitors tumor response, and dynamically adjusts the composition based on real-time genomic analysis. This enables a highly personalized and effective treatment approach. Additionally, the system can be integrated with nanoparticle delivery systems, bioresponsive linkers, and in-situ generation of tucaresol analogs within the tumor, further enhancing its capabilities.

The new claims introduce a paradigm shift in cancer treatment by integrating machine learning, real-time genomic analysis, and adaptive treatment optimization. This inventive concept is novel and non-obvious compared to the original patent, as it enables a highly personalized and dynamic approach to cancer treatment.

Alternative embodiments of the inventive concept could include the use of different machine learning algorithms, integration with other omics data, or incorporation of additional treatment modalities. Variations could also include the use of different tucaresol analogs, or the development of new bioresponsive linkers.

The inventive concept has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, targeted therapies, and precision oncology. The market for cancer treatment is rapidly growing, and this inventive concept is poised to capture a significant share of this market.